Delaware jury finds Parse infringed three genetic-sequencing patents

Scale sued Parse in 2022, alleging it infringed three cell-sequencing patents that Scale licensed from Roche. The patents' inventor Garry Nolan co-founded Scale.

Parse denied the allegations and argued that the patents were invalid. It has separately countersued Scale for infringing its patents.

Qiagen acquired Parse last December, while California-based 10x acquired Scale last August.

The jury agreed that Parse's Evercode platform, used in biomedical research, infringed patents licensed to Scale Biosciences by Roche.

Parse and Qiagen said in a statement that they were disappointed with the verdict and that Parse will "continue to vigorously defend itself in this litigation."

10x said in a statement that it would seek enhanced damages, attorneys' fees and a permanent injunction against Parse following the verdict.

In response to a request for comment, Roche referred Reuters to 10x Genomics.

A Delaware federal jury found on Friday that Parse Biosciences, a unit of Qiagen, infringed three genetic-sequencing patents licensed by Roche to Scale Biosciences, part of 10x Genomics, awarding $4.8 million in damages and finding the infringement was willful.

The willfulness finding could allow the judge to increase the damages award by up to three times.